Background--Intracellular Na + concentration ([Na + ] i ) regulates Ca 2+ cycling, contractility, metabolism, and electrical stability of the heart. [Na + ] i is elevated in heart failure, leading to arrhythmias and oxidative stress. We hypothesized that myocyte [Na + ] i is also increased in type 2 diabetes (T2D) due to enhanced activity of the Na + -glucose cotransporter.
T ype 2 diabetes (T2D) heightens the risk of developing heart failure (HF), arrhythmias, and sudden cardiac death, even in the absence of vascular complications such as coronary artery disease and hypertension. [1] [2] [3] [4] [5] Severe heart dysfunction often occurs before full-blown diabetes is diagnosed (prediabetes), [6] [7] [8] [9] suggesting an early and critical maladaptation of myocardial structure and function. The mechanisms that link T2D to the electrical and structural remodeling of the myocardium are multifactorial but poorly understood.
In the heart, intracellular Na + concentration ([Na + ] i ) and Na + transport are critical modulators of Ca 2+ cycling, contractility, energy supply and demand, oxidative state, action potential waveform, and propensity for arrhythmias. 10 [Na + ] i is elevated in HF, [11] [12] [13] [14] [15] which mitigates contractile dysfunction by favoring more Ca 2+ influx via the Na + /Ca 2+ exchanger (NCX), thus augmenting the cellular and sarcoplasmic reticulum Ca 2+ load; however, increased sarcoplasmic reticulum Ca 2+ load also raises the risk for arrhythmias. 16 At the same time, high [Na + ] i induces oxidative stress by activating the mitochondrial NCX, leading to lower free Ca 2+ in the mitochondria and slower regeneration of NADPH, which is needed to neutralize the reactive oxygen species produced in the mitochondria. [17] [18] [19] Both decreased Na + extrusion and increased Na + entry may contribute to the rise in [Na + ] i in HF, depending on the etiology of the disease. Few studies have so far investigated myocardial Na + transport in diabetes. Decreased activity of the Na + /K + pump 20, 21 (NKA) and NCX 22, 23 were reported in hearts from animals with type 1 diabetes. The myocardial Na + /H + exchanger was found to be enhanced in hearts from T2D animals, 24, 25 which contributed to left ventricular hypertrophy 24 and led to higher [Na + ] i gain during ischemiareperfusion. 25 Na + /H + exchanger inhibition was associated with a lower incidence of ventricular tachycardia and fibrillation in T2D hearts during ischemia-reperfusion 25 ; however, it is currently unknown whether myocyte [Na + ] i is altered in T2D
and how such alterations affect the progression of diabetic heart disease. We hypothesized that [Na + ] i is elevated in diabetic hearts due to enhanced Na + entry through the Na + -glucose cotransporter (SGLT), which couples the uptake of Na + ions and glucose. SGLT is present in the heart, 26, 27 but its physiological and pathophysiological roles are not fully understood. Recent data demonstrated that cardiac-specific overexpression of the SGLT1 isoform causes hypertrophy and left ventricular dysfunction. 28 The mRNA level of cardiac SGLT1 is increased in HF and T2D, 27 2 pathological conditions that render the heart insulin resistant. SGLT1 seems to be required for activation of NADPH oxidase by hyperglycemia. 29 Moreover, SGLT-mediated glucose uptake has been linked to PRKAG2 cardiomyopathy, 30 a glycogen storage cardiomyopathy caused by mutations in the gene encoding the c2 subunit of AMP-activated protein kinase. The activity of cardiac SGLT may be increased in T2D as an adaptation to both chronic hyperglycemia and the reduced ability of myocytes to take up glucose through insulin-dependent pathways. We tested this hypothesis by analyzing [Na + ] i and SGLT expression and function in hearts from rats and humans with T2D versus nondiabetic controls.
Methods Experimental Animals
The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and was approved by the institutional animal care and use committee at the University of Kentucky. The T2D animal model used in this study is the HIP rat. HIP rats are obese Sprague-Dawley rats that express human amylin, an amyloidogenic hormone cosecreted with insulin, in the pancreatic b cells on the insulin II promoter. 31 Increased amylin secretion in the insulinresistant prediabetic state causes its aggregation and deposition in pancreas in both humans 31 and HIP rats, 32 which leads to gradual decline of b-cell mass and development of full T2D. [31] [32] [33] Because rodent amylin is not amyloidogenic, HIP rats are unique within rodent T2D models in showing amylin amyloid deposition. Together with the late-onset development of T2D, this characteristic makes the HIP rat a "humanized" T2D animal model. We recently demonstrated that amylin accumulation in humans with obesity or T2D and in HIP rats is not limited to the pancreas but also occurs in peripheral organs, including the heart. 34, 35 HIP rats were monitored biweekly for nonfasting blood glucose (with a glucometer) and used in experiments when glucose was >400 mg/dL (22.5 mmol/L) for >8 consecutive weeks (ie, late-stage T2D). Age-matched wild-type (WT) littermates were used as nondiabetic controls. Because the genetic background of HIP rats is the Sprague-Dawley rat, the WT animals are also obese. In fact, the body weight of the WT rats (698AE20 g) was larger than that of HIP rats (611AE25 g) at the time they were used for experiments, due to weight loss in HIP rats after development of full-blown diabetes. Sample sizes of 20 diabetic male HIP rats and 20 WT male rats were used in this study.
Human Samples
Human left ventricular tissue was from hearts obtained at the time of orthotopic heart transplantation at the Hospital of the University of Pennsylvania (for failing hearts) or organ donation (for nonfailing hearts), in accordance with institutional review board approval and after obtaining informed consent. The hearts were divided into 5 pathological groups, depending on the presence of T2D and HF and body weight. The average age and body mass index, sex distribution, and HF etiology (ischemic versus nonischemic) of the patients in the 5 groups are shown in Table. The first group is that of hearts from patients with both T2D and HF (T2D-HF group; 4 hearts). T2D in these patients was controlled with either insulin (for 2 cases) or oral glucose-lowering drugs (n=2). Failing hearts from non-T2D patients were divided into the failing-obese (OB-HF; n=6) and failing-lean (L-HF; n=7) groups based on the body mass index of the patient (≥30 kg/cm 2 for the obese group; <30 kg/cm 2 for lean). Nonfailing hearts were also divided into OB-NF (n=6) and L-NF (n=6) groups. Equal loading was verified by reprobing with anti-GAPDH (Abcam). Signal intensity analysis was performed in ImageJ (National Institutes of Health). For each gel, we averaged the signal intensity of the corresponding bands for the control samples. We then normalized the signal intensity in all lanes to this average. This procedure was repeated on at least 4 gels, and for each sample, the normalized signal intensity was averaged. In the end, we calculated averages over all groups used.
Immunofluorescence
Freshly isolated myocytes were plated on laminin-coated coverslips, fixed with 4% paraformaldehyde, permeabilized with 50 lg/mL saponin (15 minutes), blocked with 2% goat serum, and labeled with a polyclonal primary antibody against SGLT1 (Santa Cruz Biotechnology). Anti-rabbit Alexa Fluor 488 was used as a secondary antibody, and fluorescence images were collected with a laser scanning confocal microscope.
Cardiac Myocyte Isolation
Rats were anesthetized with 3% to 5% isoflurane (100% O 2 ), then hearts were excised quickly, placed on a gravity-driven Langendorff perfusion apparatus, and perfused with 1 mg/ mL collagenase. When the heart became flaccid (%15 minutes), the left ventricular tissue was cut into small pieces, dispersed, and filtered, and the myocyte suspension was rinsed several times. In the first case, Na + efflux was mediated by both NKA and passive leak, whereas in the second case, the only contribution was that of the passive Na + leak.
Resting Na + influx was taken as the initial rate of [Na + ] i rise following abrupt NKA inhibition with 10 mmol/L ouabain.
Glucose Uptake Measurements
Myocyte glucose uptake was measured using the fluorescent glucose analog 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose, or 2-NBDG (Life Technologies). 36, 37 Myocytes were preincubated in glucose-free Tyrode's solution for 60 minutes, and then they were incubated with 1 mmol/L 2-NBDG for 30 minutes in the absence or presence of 250 lmol/L phlorizin or 50 nmol/L insulin. External 2-NBDG was washed off, and the cells were imaged with a confocal microscope using identical settings for all measurements. For each rat, we calculated the mean fluorescence intensity per group (a minimum of 20 cells per group), and we normalized the fluorescence in the phlorizin and insulin groups to the control. Measurements were repeated in cells from 6 HIP and 6 WT rats.
Statistical Analysis
The data are presented as meanAESE. For data that passed the D'Agostino and Pearson normality test, statistical discriminations were performed using a 2-tailed unpaired Student t test when comparing 2 groups and 1-way ANOVA with Bonferroni's post hoc test when comparing multiple groups. When the sample size was too small to perform the normality test, data were analyzed with nonparametric tests (Mann-Whitney when comparing 2 columns, Kruskal-Wallis followed by Dunn's post test when comparing multiple columns). Differences were considered statistically significant when P<0.05.
Results

Increased SGLT1 Protein Expression in Hearts From Diabetic and Obese Humans and Rats
We started to test the hypothesis that Na + -glucose cotransport is enhanced in T2D hearts by evaluating the Figure 1A ). Because a previous study reported an increased mRNA level of SGLT1 in HF, 27 we compared failing hearts from T2D, obese (likely in an insulin-resistant prediabetic state), and lean (metabolically normal) patients. We found that SGLT1 expression was upregulated (by 73AE13%) in hearts from patients with T2D versus nondiabetic, lean participants ( Figure 1A ). Moreover, SGLT1 expression was even increased in hearts from obese patients who were not diagnosed with T2D (by 31AE5%) ( Figure 1A ). We also noted that the presence of HF alone resulted in higher cardiac SGLT1 expression in both lean and A, Western blots with an anti-SGLT1 antibody in homogenates of failing hearts from patients with T2D (T2D-HF group; 4 hearts) or obese (OB-HF group; 6 hearts) vs lean participants (L-HF group; 7 hearts). GAPDH was used as loading control, and experiments were repeated 4 times. Bar graph in the right panel shows the relative band intensity. B, SGLT1 expression in homogenates from failing vs nonfailing human hearts from lean (top) and obese (bottom) participants. C, Western blots with an anti-SGLT1 antibody in diabetic HIP vs WT heart homogenates. D, Representative immunofluorescence images of rat (WT and HIP) myocytes labeled with an anti-SGLT1 antibody. In both cases, SGLT1 is localized at the T-tubules. HF indicates heart failure; HIP, model of late-onset T2D; L, lean; NF, nonfailing heart; OB, obese; SGLT, Na + -glucose cotransporter; T2D, type 2 diabetes; WT, wild-type. *P<0.05, **P<0.01. 27 A comparable level of SGLT1 upregulation occurred in hearts from diabetic HIP rats versus WT littermates (61AE8%) ( Figure 1C ). HIP rats develop late-onset T2D 32, 33 and, as we previously showed, manifest a cardiac phenotype that provides a good resemblance of the diabetic cardiomyopathy in humans with T2D. 34, 35 To transport Na + and glucose, SGLT has to be localized at the membrane. We assessed the distribution of SGLT1 in cardiac myocytes from HIP and WT rats by immunofluorescent labeling with an anti-SGLT1 antibody ( Figure 1D ). These experiments showed that in both WT and HIP rat myocytes, SGLT1 is positioned in a striated pattern with %2 lm between the transverse striations, which strongly suggests localization at the T-tubules. Consequently, SGLT1 is localized at the sarcolemma, and its expression is elevated in hearts from humans and rats with T2D.
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Elevated [Na + ] i in Myocytes From Diabetic Hearts
To determine whether the increase in SGLT expression in diabetic hearts affects myocyte Na + homeostasis, we mea- showed little change in the expression of NKA-a isoforms ( Figure 3C ). Indeed, NKA-a1 expression was similar in myocytes from HIP (in the prediabetic and fully diabetic states) and WT rats. The expression of the a2 subunit was reduced significantly (by 54AE4%) in the fully diabetic HIP rats ( Figure 3C) ; however, NKA-a2 represents <25% of the total NKA in rat myocytes. 40, 41 Consequently, a 50% reduction in NKA-a2 means that total NKA expression is reduced by %12.5%, which has only a minor effect on total NKA function.
Nonetheless, several studies have demonstrated that NKA-a2 has a preferential role in regulating Ca 2+ cycling and cardiac hypertrophy. [41] [42] [43] [44] A reduction in NKA activity (local or global) improves contractility; therefore, the selective downregulation of NKA-a2 may be an adaptation meant to limit the decrease in cardiac function in diabetic hearts, but lower NKA-a2 also promotes arrhythmogenesis and hypertrophy. In summary, these data indicate that NKA function is not significantly altered in HIP rat myocytes; therefore, elevated [Na + ] i must be due to increased Na + influx.
Enhanced Na + Entry Through SGLT in Myocytes From Diabetic Rats
We measured Na + influx in resting myocytes from control and diabetic rats as the slope of the initial increase in [Na + ] i on blocking NKA with 10 mmol/L ouabain ( Figure 4A and 4B Figure 4B ). Multiple pathways mediate Na + entry in cardiac myocytes.
To assess the contribution of SGLT to the excess Na + entry in myocytes from diabetic rats, we measured Na + influx with SGLT blocked by a specific pharmacological inhibitor (phlorizin, 250 lmol/L) or by omission of glucose from the external solution ( Figure 4A and 4C) . SGLT inhibition through either method had no effect on WT myocytes but significantly reduced Na + entry in myocytes from diabetic rats (to and glucose-free solution, respectively) ( Figure 4C ). In fact, with SGLT blocked, Na + influx was similar in WT and HIP myocytes. The SGLT-mediated Na + entry, calculated by subtracting the Na + influx with SGLT blocked from the total rate of Na + entry, was greatly increased in HIP versus WT myocytes ( Figure 4D ). Consequently, SGLT activity is augmented in diabetic hearts, in which it becomes an important factor in regulating [Na + ] i .
Increased SGLT-Mediated Glucose Uptake in Myocytes From Diabetic Rats
To further investigate SGLT function in myocytes from diabetic and control rats, we measured glucose uptake using a fluorescent glucose analog, 2-NBDG ( Figure 5 ). 36,37 2-NBDG is taken up into cells through both Glut transporters 45, 46 and SGLT. 47, 48 Glucose uptake was measured under control conditions, with SGLT blocked by 250 lmol/L phlorizin, and in the presence of 50 nmol/L insulin ( Figure 5 ). As expected, insulin significantly enhanced glucose uptake in myocytes from WT rats (by 43AE12%), whereas phlorizin yielded no significant effect ( Figure 5A and 5B). In contrast, insulin produced only a small (not significant) effect in myocytes from T2D rats, but SGLT inhibition greatly reduced the glucose uptake (by 33AE9%) (Figure 5A and 5C). These results suggest that diabetic hearts rely more heavily on SGLT for taking up glucose, possibly as a maladaptation to insulin resistance.
Discussion
We found increased SGLT expression in failing hearts from T2D patients compared with those of nondiabetic participants and in diabetic HIP versus WT rat hearts. HIP rat myocytes exhibited enhanced SGLT-mediated Na + (and glucose) uptake, which resulted in higher [Na + ] i . Figure 4 . Na + influx in myocytes from control and diabetic rats. A, Representative example of Na + influx measurements in resting HIP rat myocytes in the absence (Ctl) and presence of the SGLT inhibitor phlorizin (250 lmol/L). B, Na + influx calculated as the slope of the initial increase in [Na + ] i on blocking the Na + /K + pump with 10 mmol/L ouabain in myocytes from HIP and WT rats. C, Effect of SGLT inhibition with phlorizin and glucose-free external solution on the rate of Na + entry in myocytes from WT and diabetic HIP rats. D, SGLT-mediated Na + influx derived by subtracting the rate of Na + entry with SGLT blocked from the total Na + influx. The physiological and pathophysiological roles of SGLT in the heart are poorly understood. We found that SGLT-mediated Na + and glucose entry are negligible in myocytes from control rats, and that implies a minor role for SGLT in myocyte Na + and glucose homeostasis under physiological conditions. Recent studies revealed that the expression of SGLT1 mRNA in the heart is increased in T2D. 27 We hypothesized that SGLT is upregulated in diabetic hearts to compensate for the reduced ability of myocytes to take up glucose through insulin-dependent pathways and/or as an adaptation to chronic hyperglycemia. Indeed, external glucose modulates SGLT expression through a glucose-sensing mechanism. 26 In support of this hypothesis, we found that the protein expression of SGLT1 is increased in hearts from humans and rats with T2D. Obesity, in the absence of T2D, was also associated with elevated levels of cardiac SGLT1 in human hearts. SGLT inhibition (both pharmacological and through omission of glucose from external solution) greatly reduced the rate of Na + influx in myocytes from diabetic rats to a level comparable to that measured in control myocytes. This indicates that SGLT is the main pathway responsible for the excess Na + entry and thus [Na + ] i elevation in T2D myocytes. The SGLT-mediated Na + flux in our measurements is normalized to cell volume. Because many cardiomyopathies are associated with detubulation and thus lower membrane surface/volume ratio, our measurement might slightly underestimate the increase in SGLT-mediated Na + flux density (ie, normalized to membrane area). We also found that a significantly larger fraction of glucose uptake is mediated by SGLT in diabetic versus control myocytes. Together, these data indicate that T2D triggers an increase in the activity of cardiac SGLT, which leads to larger myocyte Na + entry and Na + overload. Recent studies point to a pathological role of SGLT upregulation in the heart. Mice with cardiac-specific overexpression of the SGLT1 isoform develop hypertrophy and left ventricular dysfunction.
28 SGLT1 is upregulated in transgenic mice with a mutation in the gene encoding the c2 subunit of AMP-activated protein kinase that is known to cause a glycogen storage cardiomyopathy (PRKAG2 cardiomyopathy) 30 and mediates, at least in part, the increased cardiac glucose uptake. Moreover, SGLT1 inhibition attenuated the disease phenotype. SGLT activity is also needed for NADPH activation by hyperglycemia. 29 However, the mechanisms that link SGLT function to such alterations in the structure and function of the heart are unclear. We propose that an increase in myocyte [Na + ] i due to enhanced Na + entry through SGLT is a key contributor to these pathologies.
In several HF models, the increase in myocyte [Na + ] i is due to larger Na + influx mediated by Na + channels or the Na + /H + exchanger. 11, 13 The expression of the NCX, the main route for Na + entry, is increased in HF, which may also cooperate to raise Na + influx. In contrast, our data show that in diabetic hearts, the excess Na + entry occurs mostly through SGLT.
Thus, distinct pathways are responsible for myocyte Na + overload in T2D and HF. A previous study demonstrated that SGLT expression is upregulated in HF, 27 a result confirmed by our results in human hearts; however, no data indicated a possible contribution of SGLT to Na + entry in HF. This suggests that in addition to upregulating SGLT expression, T2D also creates a milieu that promotes activation of the cotransporter. Our finding that SGLT-mediated Na + influx is %7 times higher in HIP versus WT myocytes, whereas SGLT expression increases of <2-fold support this hypothesis. Although SGLT regulation is incompletely elucidated, glucose (via N-glycosylation), 52 insulin, 53 and protein kinases A and C 26,53 raise its activity by modifying either the affinity for glucose or the maximal turnover rate.
In summary, we have demonstrated that myocyte Na + -glucose cotransport is enhanced in T2D, probably as a maladaptation to reduced insulin-mediated glucose uptake and chronic hyperglycemia. Elevated SGLT activity increases Na + influx into myocytes and causes Na + overload, which may contribute to arrhythmogenesis and oxidative stress in diabetic hearts. Although elevated [Na + ] i and Na + influx are also common in other pathological conditions (eg, HF), the major underlying mechanism in diabetic heart disease is specific to T2D.
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